Nathalie Bendriss-Vermare

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Venues

Clinical & translational immunology

Science translational medicine

Cancers

Nature communications

INSERM U1052

LIR Schering Plough (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

INSERM U1052 Jan 01 2006

France

Group leder :: Immunity, Virus, Inflammation - team therapeutic targeting of tumor cells and their immune stroma

INSERM U590 Nov 01 2002 - Jan 01 2005

France

post-doc

Education History

LIR Schering Plough Oct 01 1997 - Oct 26 2001

France

PHD

Publications

Aurélien Voissière, Carlos Alberto Gomez Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe Alexandre Cassier
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science translational medicine 16 (731) (2024)
Aurélien Voissière, Carlos Alberto Gomez Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe Alexandre Cassier
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science translational medicine 16 (731) (2024)
Jean-David Fumet, Emilie Lardenois, Isabelle L Ray-Coquard, Philipp Harter, Florence Joly, Ulrich Canzler, Caroline Truntzer, Olivier Tredan, Clemens Liebrich, Alain Lortholary, Daniel Pissaloux, Alexandra Leary, Jacobus Pfisterer, Alexandre Eeckhoutte, Felix Hilpert, Michel Fabbro, Christophe Caux, Jérôme Alexandre, Aurélie Houlier, Jalid Sehouli, Emilie Sohier, Rainer Kimmig, Bertrand Dubois, Dominique Spaeth, Isabelle Treilleux, Jean-Sébastien Frenel, Uwe Herwig, Olivia Le Saux, Nathalie Bendriss-Vermare, Andreas du Bois
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. Cancers 14 (5) (2022)
Yamila Rocca, Kevin Pouxvielh, Marie Marotel, Sarah Benezech, Baptiste N Jaeger, Omran Allatif, Nathalie Bendriss-Vermare, Antoine Marçais, Thierry Walzer
Combinatorial Expression of NK Cell Receptors Governs Cell Subset Reactivity and Effector Functions but Not Tumor Specificity. Journal of immunology (Baltimore, Md. : 1950) 208 (7) (2022)
Eleonora Sosa Cuevas, Nathalie Bendriss-Vermare, Stephane Mouret, Florence De Fraipont, Julie Charles, Jenny Valladeau-Guilemond, Laurence Chaperot, Caroline Aspord
Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80 + PDL1 - )-pDC subset negatively correlated with clinical outcomes in melanoma patients. Clinical & translational immunology 11 (5) (2022)
Raphaël Mattiuz, Carine Brousse, Marc Ambrosini, Jean-Charles Cancel, Gilles Bessou, Julie Mussard, Amélien Sanlaville, Christophe Caux, Nathalie Bendriss-Vermare, Jenny Valladeau-Guilemond, Marc Dalod, Karine Crozat
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T-cell protective responses to breast cancer. Clinical & translational immunology 10 (7) (2021)
Laurissa Ouaguia, Tania Dufeu-Duchesne, Vincent Leroy, Thomas Decaens, Jean-Baptiste Reiser, Eleonora Sosa Cuevas, David Durantel, Jenny Valladeau-Guilemond, Nathalie Bendriss-Vermare, Laurence Chaperot, Caroline Aspord
Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs. Clinical & translational immunology 9 (12) (2020)
Gael Boivin, Julien Faget, Pierre-Benoit Ancey, Aspasia Gkasti, Julie Mussard, Camilla Engblom, Christina Pfirschke, Caroline Contat, Justine Pascual, Jessica Vazquez, Nathalie Bendriss-Vermare, Christophe Caux, Marie-Catherine Vozenin, Mikael J Pittet, Matthias Gunzer, Etienne Meylan
Durable and controlled depletion of neutrophils in mice. Nature communications 11 (1) (2020)
Eleonora Sosa Cuevas, Laurissa Ouaguia, Stephane Mouret, Julie Charles, Florence De Fraipont, Olivier Manches, Jenny Valladeau-Guilemond, Nathalie Bendriss-Vermare, Laurence Chaperot, Caroline Aspord
BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clinical & translational immunology 9 (11) (2020)
Rodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, Maude Ardin, Isabelle Treilleux, Carola H Ries, Emilie Lavergne, Sylvie Chabaud, Amélie Colombe, Olivier Trédan, Henrique Gomes Guedes, Fábio Laginha, Wilfrid Richer, Eliane Piaggio, José Alexandre M Barbuto, Christophe Caux, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare
CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clinical & translational immunology 9 (2) (2020)
Margaux Hubert, Elisa Gobbini, Coline Agnes Couillault, Thien-Phong Vu Manh, Anne-Claire Doffin, Justine Berthet, Céline Rodriguez, Vincent Ollion, Janice Kielbassa, Christophe Sajous, Isabelle Treilleux, Olivier Trédan, Bertrand Dubois, Marc Dalod, Nathalie Bendriss-Vermare, Christophe Caux, Jenny Valladeau-Guilemond
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Science immunology 5 (46) (2020)

Nathalie Bendriss-Vermare.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nathalie Bendriss-Vermare